GSK BHR Study (Sont)

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: June 12, 2009
Last updated: April 11, 2013
Last verified: March 2011
The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma

Condition Intervention Phase
Drug: Placebo
Drug: FP 100mcg
Drug: FP 500mcg
Drug: FP 250mcg
Drug: FSC 100/50mcg
Drug: FSC 250/50mcg
Drug: FSC 500/50mcg
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUSTM BID or Fluticasone Propionate DISK ...

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Average inhaled corticosteroid treatment dose over the treatment period [ Time Frame: Every 8 weeks for the 40 week treatment period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pulmonary function measures [ Time Frame: Every 8 weeks for the 40 week treatment period ] [ Designated as safety issue: No ]

Enrollment: 464
Study Start Date: February 2003
Study Completion Date: October 2004
Primary Completion Date: October 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fluticasone propionate Drug: Placebo
Twice daily dosing
Drug: FP 100mcg
Twice daily dosing
Drug: FP 500mcg
Twice daily dosing
Drug: FP 250mcg
Twice daily dosing
Active Comparator: Fluticasone propionate/salmeterol combination Drug: Placebo
Twice daily dosing
Drug: FSC 100/50mcg
Twice daily dosing
Drug: FSC 250/50mcg
Twice daily dosing
Drug: FSC 500/50mcg
Twice daily dosing


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Asthma diagnosis
  • Controller medications or moderate inhaled corticosteroid dose
  • Evidence of reversibility

Exclusion Criteria:

  • Life-threatening asthma
  • Asthma instability
  • Concurrent respiratory disease
  • Drug allergy
  • Respiratory tract infection
  • Systemic corticosteroid use
  • Immunosuppressive medication use
  • Positive pregnancy test
  • Tobacco use
  • Site affiliation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00920543

United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35209
United States, Florida
GSK Investigational Site
Bay Pines, Florida, United States, 33744
United States, North Carolina
GSK Investigational Site
Statesville, North Carolina, United States, 28625
United States, Oregon
GSK Investigational Site
Tigard, Oregon, United States, 97223
United States, Washington
GSK Investigational Site
Bellingham, Washington, United States, 98226
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00920543     History of Changes
Other Study ID Numbers: SAM40086 
Study First Received: June 12, 2009
Last Updated: April 11, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Salmeterol Xinafoate
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on August 25, 2016